Verge Genomics is a next-generation drug discovery company that is using human genomics to accelerate drug discovery. Founded by scientists from leading genomics labs and pharmaceutical veterans, the Verge team is 14 people including 10 Ph.D.s with expertise in machine learning, neuroscience, drug development, applied math, biophysics, and statistics from UCLA, Stanford, Oxford, and UCSF.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/16/18 | $32,000,000 | Series A |
Agent Capital ALS Investment Fund DFJ  OS Fund WuXi AppTec | undisclosed |
| 12/16/21 | $98,000,000 | Series B |
ALS Investment Fund BlackRock Eli Lilly and Company LifeForce Capital Merck Global Health Innovation Fund Section 32 Tao Capital Partners Threshold Ventures Vulcan Capital | undisclosed |
